Low Level of Cross-Resistance to Amprenavir (141W94) in Samples from Patients Pretreated with Other Protease Inhibitors

Lignende værker

• Single-Dose Safety and Pharmacokinetics of Amprenavir (141W94), a Human Immunodeficiency Virus Type 1 (HIV-1) Protease Inhibitor, in HIV-Infected Children
  af: Yogev, Ram, et al.
  Udgivet: (2005)
• Safety and Pharmacokinetics of Amprenavir (141W94), a Human Immunodeficiency Virus (HIV) Type 1 Protease Inhibitor, following Oral Administration of Single Doses to HIV-Infected Adults
  af: Sadler, Brian M., et al.
  Udgivet: (1999)
• Nucleoside Analog 1592U89 and Human Immunodeficiency Virus Protease Inhibitor 141W94 Are Synergistic In Vitro
  af: Drusano, G. L., et al.
  Udgivet: (1998)
• Interactions of 1263W94 with Other Antiviral Agents in Inhibition of Human Cytomegalovirus Replication
  af: Selleseth, Dean W., et al.
  Udgivet: (2003)
• Predictive Values of the Human Immunodeficiency Virus Phenotype and Genotype and of Amprenavir and Lopinavir Inhibitory Quotients in Heavily Pretreated Patients on a Ritonavir-Boosted Dual-Protease-Inhibitor Regimen
  af: Barrail-Tran, Aurélie, et al.
  Udgivet: (2008)